Risk Stratifying Interstitial Lung Abnormalities to Guide Early Diagnosis of Interstitial Lung Diseases

Abstract

Delayed diagnosis is common in interstitial lung diseases (ILDs) and is associated with decreased quality of life and a poor prognosis (1). Early diagnosis and initiation of appropriate management could improve patient outcomes (2–5). Studies in idiopathic pulmonary fibrosis (IPF) demonstrated that antifibrotic therapies also slow down disease progression in patients with more preserved lung function (3, 5). Interstitial lung abnormalities (ILAs) found incidentally on computed tomography (CT) performed for other purposes, such as lung cancer screening or diagnostic cardiac CT, may facilitate early diagnosis of ILD, allowing for early treatment and removal of triggers that drive ILD progression. However, ILAs are relatively frequent, especially in older subjects (6). Systematic evaluation of population-based and lung cancer–screening cohorts showed a prevalence of ILAs of 4–9% in (former) smokers and 2–7% in never-smokers (7). With increasing use of CT scans, clinicians are confronted with the question, “what to do with this person with ILAs?” Risk stratification of ILAs is urgently needed to differentiate two subsets: 1) ILAs with a high likelihood of progression to clinically relevant ILD; versus 2) ILAs that pose no such risk and do not need further evaluation and follow-up. In this issue of the Journal, Rose and colleagues (pp. 60–68) add another piece of evidence to the puzzle of risk stratification of ILAs (8). They investigated whether combining CT data and pulmonary function (spirometry and Dl CO) could identify subjects with suspected ILD, associated with worse outcomes, within participants with ILAs in the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease (COPDGene) cohort, a U.S.-based multicenter prospective cohort study of (current and former) smokers (9). People with known lung diseases other than COPD or asthma were excluded. CT scans were assessed for percentage of emphysema and ILAs, defined per criteria of the Fleischner Society (10). CT scans showing ILAs were scored on the presence of definite fibrosis. Importantly, Dl CO was corrected for the percentage of emphysema on CT. For suspected ILD, the authors used the following definition: presence of ILAs and at least one of the following three criteria: 1) definite fibrosis on CT; 2) post-bronchodilator FVC < 80% predicted; or 3) Dl CO < 70% predicted after adjustment for emphysema. Ten percent of participants (443 out of 4,360) had ILAs. Of those with ILAs, 239 (54%) met the criteria of suspected ILD; within this subset, 16% had definite fibrosis on CT, 57% had an FVC < 80%, and 67% had a Dl CO < 80% after adjustment for emphysema. The majority (62%) of participants with suspected ILD met only one criterium, 35% met two criteria, and 3% met all three criteria. Participants with suspected ILD were more likely to be of self-identified Black or African American race and had a higher pack-year smoking history. Compared with the ILA group, subjects with suspected ILD were more likely to have worse clinical endpoints (including quality of life, 6-minute-walk test, and respiratory exacerbations). Mortality rates were higher in the suspected ILD than in the ILA group (15% vs. 6%). This study has several strengths, including the large, multicenter, prospective cohort design with longitudinal data collection. The authors take the important step of splitting ILAs in two separate subgroups with vastly different outcomes: ILAs versus suspected ILD. Although ILA is a CT-defined entity, suspected ILD is defined by a combination of radiological and physiological abnormalities and could be seen as a potential early phase in the evolutionary continuum of ILD (11). However, suspected ILD and even definite ILD is not a diagnosis but merely an umbrella term warranting further investigations, ideally in an experienced ILD center with a multidisciplinary team discussion (11, 12). Although it feels intuitively correct to refer subjects with suspected ILD for further work-up and follow-up, it is too early to conclude that people with ILAs without suspected ILD can be safely discharged from follow-up. The study also has limitations. First, the COPDGene cohort studied only smokers, implicating the need to further validate and fine-tune the criteria of suspected ILD in broader populations. Second, although a Dl CO < 70% predicted (after adjustment for emphysema) appeared to be the most important criterium in driving the associations with clinical endpoints, Dl CO was not measured at baseline but only in the second phase of COPDGene (5 years after enrollment). Replication of the lung function criteria (and their cut-offs) is warranted in independent cohorts with contemporaneous imaging, spirometry, and Dl CO data. Moreover, it is a concern that the single criterium of an often-variable measure such as Dl CO is sufficient to support labeling a person as having suspected ILD. Last, another potential caveat is the fact that the presence of subpleural reticulation was not included in the criteria for suspected ILD. This conforms to the Fleischner criteria, where the division is made in subpleural nonfibrotic ILA and subpleural fibrotic ILA (characterized by the presence of architectural distortion with traction bronchiectasis or honeycombing) (10). However, a recent population-based ILA study in China showed that subpleural reticulation in itself was an independent risk factor for progression (6). Strikingly, the distribution of suspected ILD in COPDGene is equal in males and females, which is not reflecting the prevalence of IPF in registries and studies (13). Furthermore, there is a considerably lower death rate in subjects with suspected ILD than in patients with IPF. Besides a potential lead-time bias, this suggests that ILAs likely encompass the broad spectrum of ILDs. As the presence of connective tissue diseases or occupational exposures were not an exclusion criterium for participating in the COPDGene cohort, this may partially explain the survival and sex distribution, where the suspected ILD could be related to connective tissue disease or exposure. For this group, early detection of ILD may be most relevant, as immunosuppressive treatments and avoidance of disease triggers have the potential to reverse, stabilize, or slow down lung function decline (11). In the current study, self-identified Black race was a risk factor for suspected ILD. Previous studies have shown that women and people of Black ethnicity are less likely to receive a diagnosis of IPF and are underrepresented in registries and clinical trials (13, 14). Identifying suspected ILD in the group of ILAs—according to the approach by Rose and colleagues—may be a way to improve earlier diagnosis in broader and more diverse populations. The results of this study underline that people with ILAs should undergo lung function testing, in line with previous expert recommendations (7, 10). The question remains, though, whether people with ILAs can be discharged from follow-up if lung function is normal and there are no signs of definite fibrosis on CT. Although several studies have identified blood biomarkers and genetic polymorphisms related to the presence of ILAs, limited data exist on biomarkers predictive of ILA progression (15, 16). It would be interesting to link the proposed suspected ILD classification with biomarkers and genetic data in COPDGene. Taken together, the findings of Rose and colleagues support that it is time to complement the CT-based ILA classification with a clinical classification of suspected ILD, also incorporating lung function and potentially symptoms and blood biomarkers to identify patients as early as possible in the evolutionary continuum of the different ILDs. Such a holistic classification would pave the way for clinical trials investigating the long-term benefits of treating ILDs in the early phases, to improve outcomes for patients with often still poor prognoses.